Dainippon Sumitomo Pharma Partners With Bristol-Myers K.K. On Anti-Hypertension And Hepatocellular Cancer Drugs
Japanese firm Dainippon Sumitomo Pharma (DSP) and Bristol-Myers K.K. (BMKK) will collaborate to co-develop and market irbesartan, an anti-hypertension drug and SM-11355 (miriplatin hydrate), a drug for hepatocellular cancer.
Irbesartan, one of the top selling an angiotensin receptor blockers (ARB), is currently on Phase III trials in Japan. SM-11355, on the other hand, is a lipophilic platinum complex, under Phase II development as an hepatic arterial injection chemotherapy suspended in lipiodol to treat hepatocellular carcinoma or liver cancer.
DSP and BMKK will be able to co-market the drug following DSP's obtaining manufacturing and marketing approval.
Sources: DSP press release (pdf), JCN Newswire
Comment Preview